Oncology Information

Want to keep updated with our latest videos and podcasts? Please sign up to receive our newsletter! eepurl.com/cxXqHj

⚡️Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy with TP53 Mutation #BladderCancer @mjmoussa_ @OAlhalabiMD @Parminder1699 @AlanBryce9 @SaadAtiq24 @apolo_andrea @CurrentOncology @PavlosMsaouel mdpi.com/1718-7729/31/6…

🙋‍♂️GU friends, don't make plans for Saturday21st, Sunday 22nd and Monday 23rd of October... At least 4 phase 3 potentially practice changing trials will be presented at #ESMO2023. Congratulations to all the @myESMO team for such exciting program. Can't wait to seeing the data and welcome you all in Madrid!!!! @OncoAlert @DrChoueiri @apolo_andrea @AlbigesL @tompowles1 @neerajaiims @montypal @PGrivasMDPhD @y_loriot @MRoupret @GuardConsortium @amerseburger @JimCatto @MattGalsky

New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to @DrChoueiri and Mike Atkins for help assembling data.

@montypal @neerajaiims @cityofhope @KidneyCancer @kidneycan @ASCO @SWOG @DrRaviSalgia @DrChoueiri @PGrivasMDPhD @VivekSubbiah @TiansterZhang @drenriquegrande @VanitaNoronha @OncoAlert @PauloBergerot @crisbergerot @TDorffOnc @NazliDizman @LuisMezaco @ZeynepZengin Congratulations dr Pal!!!!👏👏👏👏

@neerajaiims @cityofhope @KidneyCancer @kidneycan @ASCO @SWOG @DrRaviSalgia @DrChoueiri @PGrivasMDPhD @VivekSubbiah @TiansterZhang @drenriquegrande @VanitaNoronha @OncoAlert One of the best things about turning 40 is looking back at the past decade of @cityofhope faculty life & thinking of all the great friends I've made amongst patients, trainees & colleagues. My 30s have been a blast & my job has taught me not to take the act of living for granted!

Before @montypal hit 30, his goal was to have 30 MEDLINE-cited papers. He then set his sights on >400 by 40 & elevated many trainees along the way. Congrats on hitting this personal milestone just ahead of your big day! @cityofhope @KidneyCancer @kidneycan bit.ly/3wAbTQO

For my colleagues in #GeriOnc, nice article led by @DVAraujoMD & @ShaanDudani looking at age & outcome w ICIs in #kidneycancer. The @IMDConline strikes again (thx @DrDanielHeng @DrChoueiri) suggesting no diff in OS based on age; RR diff in 1L intriguing?

Fantastic review of Wnt/b-catenin signaling in #bladdercancer by @arafflemd w mentoring from @YungLyou. Alex is a star fellow & will be giving GR at @HarborUCLA on Tues re: this & projects w @TDorffOnc & me. He will be looking for a jr faculty position next yr; DM me for his CV!

Prof. Guillermo Gracia-Manero, @garciamanero, chief section of MDS Deputy Chair, Transitional Research Department of Leukaemia, MD Anderson Cancer Center , summarizes the most important data presented at the 62nd ASH Annual Meeting 2020 in MDS youtu.be/m_PoDBxRoIU

Prof. Joseph R. Mikhael, @jmikhaelmd Chief Medical Officer of the International Myeloma Foundation, summarizes the most important data presented at the 62nd ASH Annual Meeting 2020 in Multiple Myeloma. youtu.be/quEdCheLSK0

Our Dr. Steven Sherman has led thyroid cancer clinical trials for decades. So when the chance arose to enroll in a COVID-19 vaccine trial, he didn’t hesitate. bit.ly/3m8ZpKr @StevenISherman #COVID19 #EndCancer

Everyone should get vaccinated with #COVID19 vaccine for the sake of the most frail citizens in the community. No excuses please. Vaccine is approved now.

"Cancers need sugar -> stop eating sugar to cure cancer". Unfortunately, no. 3 negative clinical trials of low/no-carb diet for #glioblastoma this month, and one elegantly used #MRI scans to look at energy levels in the cancer; diff diets -> no difference mdpi.com/2072-6694/12/1…

Congratulations ⁦@NGoelMD⁩ for an important presentation ⁦⁦@SABCSSanAntonio⁩ on racial disparities in breast cancer outcomes. ⁦@SylvesterCancer⁩ ⁦@umiamimedicine⁩

Only 5-8% of adults with cancer enroll in a clinical trial during treatment. We teamed up with @LLSusa's Clinical Trial Support Center to help ASH members support their patients to find and enroll in #clinicaltrials. ➡️Learn more: bit.ly/3kllZiZ

#ASHFromHome is one of our featured #ASH20 hashtags! During the annual meeting, we will have a prompt for you to follow along with each day—for a nice “brain 🧠 break” and some fun with colleagues. See this thread🧵 of prompts to get ready for all the fun:

Very nice review of importance of MRD and recognition/management of toxicities of novel agents for #AMLsm that Jeff Lancet @MoffittNews somehow masterfully managed to cover in less than 20 minutes in @aamdsif @ClevelandClinic symposium @ASH_hematology #ASH20 #ASH2020 #ASHTogether

Seeing data for sacituzumab at #ESMO20 from @y_loriot @PGrivasMDPhD et al. Does anyone know if expression of nectin-4 & trop-2 overlap in #bladdercancer? Are there populations that may benefit from one or the other?

#ESMO20 @myESMO Danube phase 3 with dual checkpoint blockade versus stand. chemoRx fails to improve outcomes. Upfront chemotherapy -> higher responses. Biomarkers needed to select pts for this strategy. @tompowles1 @OncoAlert

Key @myESMO #bladdercancer presentations #ESMO20 #ESMO2020

Again, the long awaited #DANUBE in bladder cancer exploring single, double IO vs. chemo failed to show a PFS/OS benefit. @OncoAlert @tompowles1 @OncoBellmunt @myESMO Maintenance avelumab post chemo remains standard/Need to learn how to integrate EV/other new drugs #ESMO20

#ESMO20 Clinically significant OS results for sacituzumab govitecan in triple negative #BCSM after 2 or more chemotherapies